Navigation Links
Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Date:10/25/2009

based on a normal Body Mass Index, or BMI, of 25. In addition to the previously announced improvements in glycemic parameters, including fasting glucose, fasting insulin and HOMA-IR, lorcaserin patients also achieved highly significant improvements in HbA1C over one year of treatment (p<0.0001). The greatest improvements were observed in patients with abnormal baseline values.

Quality of Life, as assessed by the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire, also improved to a significantly greater extent in the lorcaserin group than the placebo group at Week 52 (p<0.005). Lorcaserin patients achieved improvements over placebo in all subscores of the IWQOL-Lite, including physical function, self esteem, sexual life, public distress and work.

In addition to the previously announced tolerability data, today's presentation also reported that lorcaserin demonstrated no increase in depression or suicidal ideation compared to placebo. Depression and suicidal ideation were monitored prospectively using the Beck Depression Inventory-II (BDI-II) and by adverse event reporting. At Week 52, 18.0% of lorcaserin patients and 16.1% of placebo patients reported at least a five-point improvement from baseline in BDI-II. A smaller number of lorcaserin patients had increases in the BDI-II total score as compared to placebo. Adverse events related to depression and their total rates at Year 1 for patients who took lorcaserin or placebo, respectively, were 3.1% and 3.0%. In addition, cumulative incidence of suicidal ideation was prospectively evaluated by administration of the BDI-II Questionnaire and did not differ between the lorcaserin and placebo groups at each measurement through two years of treatment.

Christen M. Anderson, M.D., Ph.D., Arena's Vice President of Clinical Development stated, "Drug candidates that act on the central nervous system are currently under tremendous scrutiny for any association with depressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. UCLA/RAND study shows that many children of HIV-positive parents are not in their custody
3. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
4. Nutrition model stresses positive experience of eating
5. Ultrasound plus mammography finds more cancers, but increases false positives
6. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
7. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
8. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
9. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
10. A low prevalence of H pylori in HIV-positive patients
11. Drug Company-Funded Asthma Drug Studies More Positive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are ... calling a physician. In an effort to share more and better information with ... Pennsylvania to publicly share patient satisfaction ratings and comments about its doctors and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, a leading global ... that John Munro, a 15-year veteran of the eDiscovery services industry, has joined ... “I am thrilled to join Discovia at this important point in its evolution,” ...
(Date:8/4/2015)... New York (PRWEB) , ... August 04, 2015 ... ... exceptional dietary supplement manufacturing, label design, product packaging, and fulfillment services, joined over ... Challenge. The event was held on Tuesday, July 28th at Jones Beach ...
(Date:8/4/2015)... Louis, Missouri (PRWEB) , ... August 04, 2015 ... ... Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership team ... track record of sales success at technology companies and expanding global markets with ...
(Date:8/4/2015)... ... 04, 2015 , ... Patients are invited to take advantage ... renowned Beverly Hills facelift surgeon , Dr. Paul Nassif. The opportunity to ... to achieve an outer appearance that meets their personal goals. This consultation with ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3
... Will Earn Decision Resources, Gold Standard for Rheumatoid ... from Decision ResourcesWALTHAM, Mass., Jan. 28 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... on reducing the signs and symptoms of rheumatoid ...
... Data Show Significant Reduction In Snoring Events, Increase ... 28 AirWare, Inc., maker of Brez premium ... for inside the nose clinically proven to reduce ... bed partner, today announced availability in all Rite ...
... shows that very low amounts of Micromet,s EpCAM-targeting BiTE ... 28 Micromet, Inc. (Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune diseases, today announced ... Immunobiology describing in detail the mode of action ...
... BD (Becton, Dickinson and Company) (NYSE: BDX ... first fiscal quarter ended December 31, 2008, representing an increase ... quarter,s growth rate reflects the unfavorable impact from foreign currency ... percentage points. "BD is off to a solid start ...
... Inc. (Pink Sheets: PCIR) today announced it has entered ... spin off its wholly owned subsidiary, Prepaid Tel.com, Inc., ... firm which, once it has gone public, will reward ... company.The agreement with TransPacific Telecom, Inc., the developer of ...
... have delivered the world’s first commercially cloned dog, a 10-week old ... , ... Boca Raton, FL (Vocus) January 28, 2009 -- ... commercially cloned dog, a 10-week old Labrador named Lancey, to Florida ...
Cached Medicine News:Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 2Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 2Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 3Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 5Health News:BD Announces Results for First Fiscal Quarter 2Health News:BD Announces Results for First Fiscal Quarter 3Health News:BD Announces Results for First Fiscal Quarter 4Health News:BD Announces Results for First Fiscal Quarter 5Health News:BD Announces Results for First Fiscal Quarter 6Health News:BD Announces Results for First Fiscal Quarter 7Health News:BD Announces Results for First Fiscal Quarter 8Health News:BD Announces Results for First Fiscal Quarter 9Health News:BD Announces Results for First Fiscal Quarter 10Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:First Commercially Cloned Dog Delivered to Florida Family 2
(Date:8/4/2015)... MADISON, N.J. and LOS ... Quest Diagnostics (NYSE: DGX ), the world,s ... that it has completed the previously announced acquisition ... As a result of the ... Quest,s extensive range of innovative services and network ...
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported net ... three and six months ended June 30, 2015, respectively, ... $43.4 million for the same periods in 2014. Isis, ... more than $90 million of revenue Isis earned in ... Bayer to license  ISIS-FXI Rx .  Isis increased its ...
Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: